Hepatitis C
CROI 2012: Telaprevir and Boceprevir Improve Sustained Response Rates in HIV/HCV Coinfected Patients
- Details
- Category: HCV Treatment
- Published on Wednesday, 07 March 2012 00:00
Adding a first-generation HCV protease inhibitor to pegylated interferon/ribavirin dramatically increases the likelihood of 12-week sustained virological response among HIV/HCV coinfected people, researchers reported Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) in Seattle.
CROI 2012: New Hepatitis C Drugs in Clinical Practice [VIDEO]
- Details
- Category: HCV Treatment
- Published on Wednesday, 07 March 2012 00:00
New therapies are leading to a "huge sea change" in the way infectious disease doctors are thinking about hepatitis C, Douglas Dieterich suggested at a press conference at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.
Canadian Researchers Make Progress in Quest for Hepatitis C Vaccine
- Details
- Category: HCV Vaccines
- Published on Tuesday, 21 February 2012 00:00
Researchers at the University of Albert say they have discovered a new vaccine candidate that stimulates immune response against all genotypes of hepatitis C virus (HCV). The variability of the virus enables it to elude the immune system and has so far hampered efforts to develop an effective vaccine.
Hepatitis C Advocates Call for Early Studies of Interactions with New HCV Drugs
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 28 February 2012 00:00
Experimental direct-acting antiviral agents for hepatitis C virus (HCV) should be tested for drug-drug interactions with antiretroviral agents for HIV and other medications commonly used by people with hepatitis C before they are combined with other drugs in clinical trials, according to a statement by an international Hepatitis C Community Advisory Board.
Managing Side Effects of New Hepatitis C Protease Inhibitors
- Details
- Category: HCV Treatment
- Published on Tuesday, 14 February 2012 00:00
Adding the recently approved hepatitis C virus (HCV) protease inhibitors boceprevir (Victrelis) or telaprevir (Incivek) to pegylated interferon plus ribavirin can shorten the course of treatment and increase the likelihood of a cure, but can also lead to more adverse events. Fortunately, side effects are typically mild-to-moderate and usually can be managed without stopping therapy, according to a recent review.
Good 12-Week HCV Suppression with Oral Telaprevir/VX-222/Ribavirin Combo
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 24 February 2012 00:00
More than 80% of previously untreated genotype 1 chronic hepatitis C patients treated with an all-oral triple regimen including the approved HCV protease inhibitor telaprevir (Incivek), the experimental non-nucleoside polymerase inhibitor VX-222, and ribavirin experienced full viral suppression after 12 weeks of therapy, Vertex reported this week.
New Hepatitis C Helpline Offers Information and Referrals
- Details
- Category: HCV Policy & Advocacy
- Published on Tuesday, 07 February 2012 00:00
On February 1, The Support Partnership for Hepatitis C (TSP) launched a new project to connect people living with hepatitis C to resources and services in their communities.
Hard-to-Treat Hepatitis C Patients Relapse after Stopping Interferon-Free GS-7977/Ribavirin Regimen
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 21 February 2012 00:00
A majority of prior null responders with difficult-to-treat hepatitis C virus (HCV) genotype 1 experienced viral rebound after completing treatment with an all-oral regimen of the HCV nucleotide polymerase inhibitor GS-7977 plus ribavirin.
Coffee May Reduce Fibrosis in People with Fatty Liver Disease
- Details
- Category: Fibrosis & Cirrhosis
- Published on Tuesday, 07 February 2012 00:00
A new study published in the February 2012 issue of Hepatology adds to the evidence that drinking caffeinated coffee may help slow or prevent progression of liver damage, this time in people with nonalcoholic fatty liver disease (NAFLD).
More Articles...
- FDA Lifts Hold on Idenix HCV Polymerase Inhibitor IDX184
- Combining HCV Med Boceprevir with Boosted HIV Protease Inhibitors Can Lower Drug Levels
- European Study Does Not See Rapid Long-Term Liver Fibrosis in HIV/HCV Coinfected People
- Researchers Show How Cholesterol Receptor Promotes HCV Cell Entry
- High Rate of Sustained Response with Interferon-Free Daclatasvir + Asunaprevir for Hepatitis C
Web Design and Development by